


Notch and Cancer



Athens, Greece 2008

PROGRAM

4- 8 October 2008

Sponsored by



FONDATION SANTÉ

With the kind support of



Genentech
IN BUSINESS FOR LIFE

REGENERON

biogen idec

www.TheNotchMeeting.org

Notch and Cancer

4-8 October 2008

Athens-Greece

Presentations at the Notch and Cancer Conference may not be considered as published scientific papers and may not be cited or reported in the press except as personal communications (with the presenter's permission). Given these assurances we hope you will speak openly and not introduce any data or experiments that you are not prepared to discuss in full. In participating in the conference you agree neither to record presentations or posters by electronic or photographic means, nor to make printed references to the Notch and Cancer conference presentations, posters and discussions. You will also agree to omit references to the Notch and Cancer conference from any publication.

PROGRAM

Talks will be 30 minute long, including discussions.

SATURDAY, OCTOBER 4, 2008

16:00 – 22:00 Registration (The Ionic Centre, 11 Lysiou St., in the area of Plaka)
20:30 Cocktails (The Ionic Centre)

SUNDAY, OCTOBER 5, 2008

POSTER SESSION

09:00 - 09:15 Opening Remarks

09:15 - 11:00 **I. Mechanistic Aspects of Oncogenic Notch Activity-1**

Chair: Stephen Blacklow

Stephen **Blacklow** (Brigham & Women's Hospital, Harvard Medical School, USA)

“Mechanistic Aspects of Pathogenic Notch1 Signaling in T-ALL”

Barbara **Osborne** (University of Massachusetts, USA)

“Notch Mediates G1/S Cell Cycle Progression in T Cells via Cyclin D3 and its dependent kinases”

Freddy **Radtke** (Ecole Polytechnique Federale de Lausanne, Switzerland)

“Atopic dermatitis and associated hematological malignancies arise from loss of Notch signaling in the skin”

11:00 - 11:30 Coffee Break

11:30 – 12:30

II. Mechanistic Aspects of Oncogenic Notch Activity-2

Chair: Barbara Osborne

Stefano **Stifani** (Montreal Neurological Institute, McGill University, Canada)

"Function and regulation of Groucho proteins in development and cancer"

Makoto Mark **Taketo** (Kyoto University, Japan)

"Suppression of colon cancer metastasis by Aes through inhibition of Notch signaling"

12:30 - 13:30

III. The Involvement of Notch in Leukemias-1

Chair: Irv Bernstein

Jon **Aster** (Brigham and Woman's Hospital, USA)

"Novel Notch Pathway Inhibitors and Enhancers"

Iannis **Aifantis** (NYU Cancer Institute, NYU School of Medicine, USA)

"Notch signaling and the regulation of leukemic cell metastasis"

13:30 - 16:00

Lunch Break

16:00 - 18:00

IV. The Involvement of Notch in Leukemias-2

Chair: Warren Pear

Irv **Bernstein** (Fred Hutchinson Cancer Research Center, USA)

"Notch-mediated Regulation of Hematopoietic Stem/Progenitor Cells"

Adolfo **Ferrando** (Columbia University, USA)

"Gamma-secretase inhibitors reverse glucocorticoid resistance"

Warren **Pear** (University of Pennsylvania, USA)

"Notch1 transcriptional regulation: does it play a role in leukemia?"

James **Griffin**, DFCI/Harvard, USA

"Role of Notch as an Oncogene"

18:00 – 18:20

Coffee Break

18:30 - 19:30

V. Novel experimental models-1

Chair: Tom Gridley

Maria **Dominguez-Castellano** ((Instituto de Neurociencias de Alicante, UMH-CSIC. Spain - USA)

"Interplay between Notch and JAK/STAT pathways in tumorigenesis"

Tom **Gridley** (The Jackson Laboratory, USA)

"Notch Signaling During Development and Disease in Mice"

MONDAY, OCTOBER 6, 2008

POSTER SESSION

09:00: - 10:30

VI. Novel experimental models-2

Chair: Iannis Aifantis

Isabella **Screpanti** (Sapienza University of Rome, Italy)
Mutation-independent Notch3 activation in T cell leukemia

Sylvia **Fre** (Institut Curie, France)
“Notch and Wnt signals cooperatively control cell proliferation and tumorigenesis in the intestine”

Paul **Jolicoeur** (Clinical Research Institute of Montreal, Canada)
“Overexpression of Notch1 intracellular domain induces mammary stem/progenitor cell expansion in mice”

10:30 - 11:00

Coffee Break

11:00 - 12:00

VII. Novel experimental models-3

Chair: Adolfo Ferrando

David **Carbone** (Vanderbilt University, USA)
“Inhibition of tumor growth and improved T cell function by restoration of Dll1-Notch signaling in bone marrow precursors”

Shigeru **Chiba** (Graduate School of Comprehensive Human Sciences, University of Tsukuba, Japan)
“Dual antitumor mechanisms of Notch signaling inhibitor in a xenograft model”

12:00 - 14:00

VIII. Solid Tumorigenesis

Chair: Anna Bigas

Hakan **Axelsson** (University of Lund, Sweden)
“Notch signaling in renal cell carcinoma”

Meenhard **Herlyn** (The Wistar Institute, USA)
“Notch signaling in melanocyte differentiation and transformation”

Thao **Dang** (Vanderbilt-Ingram Cancer Center, USA)
“Strategies in targeting Notch3 in lung cancer”

Lluís **Espinosa** (IDIBELL, Spain)
“Notch is an essential mediator downstream of b-catenin in colorectal cancer”

Xing **Fan** (University of Michigan, U.S.A.)
“Targeting CD133 positive cancer stem cells in glioblastoma by Notch pathway blockade”

14:00 - 15:30

Lunch Break

15:30 – 17:00

IX. Notch Activation and Cell Proliferation-1

Chair: Sarah Bray

Spyros **Artavanis-Tsakonas** (Harvard Medical School, USA)
“Probing the Involvement of Notch in proliferation”

Tony **Capobianco** (The Wistar Institute, USA)
“Nic and NACK, and other insights into Notch Activation”

Sarah **Bray** (Cambridge University, UK)
“Notch and proliferation; targets and context”

17:00 – 17:30

Coffee Break

17:30 - 18:30

X. Notch Activation and Cell Proliferation-2

Chair: Maria Dominguez-Castellano

Gian-Paolo **Dotto** (University of Lausanne, Switzerland)
“Notch signaling in the integrated control of skin homeostasis and carcinogenesis”

Gianni **Del Sal** (Laboratorio Nazionale CIB, Trieste, Italy)
“The prolyl-isomerase pin1 is a novel Notch1 target that enhances Notch1 activation in cancer”

18:30 – 19:30

XI. Angiogenesis

Chair: Jan Kitajewski

Jan **Kitajewski** (Columbia University, USA)
“Notch regulates tumor angiogenesis by diverse mechanisms”

Gavin **Thurston** (Regeneron Pharmaceuticals, USA)
“VEGF and Dll4-Notch: interacting signaling pathways in tumor angiogenesis”

TUESDAY, OCTOBER 7, 2008

POSTER SESSION

09:00 - 11:30

XII. Notch in breast cancer

Chair: Bob Callahan

Hippokratis **Kiaris** (University of Athens, Greece)
MMTV-hN1IC transgenic mice as a model to study the transition of mammary hyperplasia to adenocarcinoma

Keith **Brennan** (University of Manchester, UK)
“Notch signalling regulates apoptosis in breast epithelial cells through Akt”

Bob **Callahan** (National Cancer Institute, USA)
"Notch signaling and mammary tumorigenesis"

Sean **Egan**, (The Hospital for Sick Children, Canada)
"Notch signaling and breast cancer in humans and mice"

Lucio **Miele** (Loyola University, USA)
"Crosstalk between Notch-1 and the estrogen receptor alpha in breast cancer"

11:30 - 11:50 Coffee Break

11:50 – 13:50 **XIII. Notch Signaling Agonists and Antagonists as Tumor Therapeutics**

Chair: Bin-Bing Stephen Zhou

Marc **Vooijs** (UMC, Utrecht, the Netherlands)
"Metalloprotease dependent cleavage of Notch receptors"

Dmitry **Gabrilovich** (University of South Florida, USA)
"Notch signaling in regulation of abnormal myeloid cell differentiation in cancer"

Chris **Siebel** (Genentech, Inc., USA)
Stabilizing Receptor Quiescence with Synthetic Antibodies Enables Precise Control of Notch Signaling In Vivo

Bin-Bing Stephen **Zhou** (Tanox, Inc., USA)
"NOTCH3 specific modulatory antibodies: implications for Notch regulation and development of Notch-selective anti-tumor therapeutics"

13:50 - 15:30 Lunch Break

15:30 – 17:00 **XIV. Stem Cells**

Chair: Maria Dominguez-Castellano

Sudhir **Krishna** (National Centre for Biological Sciences (TIFR), India)
"Induction of enhanced tumorigenicity and stemness in human cervical cancer cells is linked to switc"

Ronald **McKay** (LMB/NINDS/NIH, Bethesda, MD, USA)
"Regeneration mechanisms in the injured brain"

Charles **Eberhart** (Johns Hopkins University School of Medicine, USA)
"Induction of Eye Tumors by Notch3"

17:00 Closing Remarks

WEDNESDAY, OCTOBER 8, 2008

09:00 **Optional tour**
Guided tour to the Acropolis and the Ancient Agora of Athens

POSTER SESSION

Diana **Bellavia** (Sapienza University of Rome, Italy) **1**

“Specific and unique relationship between Notch3 and Jagged1 in T cell Leukemia”

Authors: D. Bellavia, M. Mecarozzi, AF. Campese, M. Pelullo, R. Palermo, A. Giovenco, A. Gulino, I. Screpanti

Maurizio **Bocchetta** (Loyola University Chicago, U.S.A.) **2**

“Opposite effects of Notch-1 and Notch-2 on mesothelioma cell survival are mediated through the Akt p”

Authors: I. Graziani, M. A. De Marco, Y. Chen, H. I. Pass, R. M. DeMay, P. R. Strack, L. Miele, M. Bocchetta

Tilman **Borggrefe** (Max-Planck-Institute, Germany) **3**

“ETO, but not AML1/ETO, augments RBP-J/SHARP-mediated repression of Notch target genes”

Authors: Tilman Borggrefe, Daniela Salat, Robert Liefke, J. Wiedenmann and Franz Oswald

Sotiria **Boukouvala*** (Exelixis, Inc., USA.) **4**

“Mutational analysis of human *NOTCH1*, *2* and *3* genes in cancer cell lines and solid tumors”

Authors: Sotiria Boukouvala*, Valentina Vysotskaia and Lisa Kadyk

**Presenting author's current affiliation:* Democritus University of Thrace, Department of Molecular Biology and Genetics, Alexandroupolis, Greece

Saula **Checquolo** (Dep. Experimental Medicine. Sapienza University of Rome, Italy) **5**

“The E3 ubiquitin ligase c-Cbl regulates Notch3 and pTa intracellular turnover in T cell leukemia”

Authors: S. Checquolo, D. Bellavia, G. Ferrara, S. Cialfi, R. Palermo, C. Oliviero, A. Gulino, I. Screpanti

Mark Y. **Chiang** (University of Pennsylvania, U.S.A.) **6**

“Leukemia-associated Notch1 alleles are weak tumor initiators, but impose Notch "addiction" on K-ras initiated leukemia”

Authors: Mark Y. Chiang, Lanwei Xu, Olga Shestova, Sarah L'Heureux, Jon C. Aster, Warren S. Pear

Natalie **Cook** (Cancer Research UK Cambridge Research Institute, UK) **7**

“Pharmacological and genetic inhibition of the Notch pathway in pancreatic cancer”

Authors: Meredith Caldwell, Natalie Cook and David Tuveson

Cynthia **Guidos** (Hospital for Sick Children, Toronto, ON, Canada) **8**

“Co-operation between Notch, IL-7 and pre-TCR signaling in normal and leukemic T cell development”

Authors: Irina Matei, Peggy Wong, Julie Yuan, Jayne Danska, Cynthia Guidos

S. **Indraccolo** (Dept. of Oncology and Surgical Sciences-University of Padua, Italy) **9**

“Angiogenesis unmasks the tumorigenic potential of dormant cancer cells through the Dll4-Notch3 inter”

Authors: S. Indraccolo¹, S. Minuzzo², M. Masiero², I. Pusceddu¹, L. Persano², L. Moserle², R. Zamarchi¹, I. S

Raquel **Goncalves** (Institute of Biomedical Engineering (INEB), Portugal) **10**

“Jagged-1 Nanostructured Surfaces are able to induce Apoptosis and Differentiation of Leukemic cells”

Authors: Raquel Goncalves, M. Cristina L. Martins, Graca Almeida-Porada, Mario Barbosa

Sugata **Manna** (Center for Molecular Pathology, Department of laboratory Medicine, Lund University, Sweden) **11**

“Notch signaling in urothelial carcinoma”

Authors: Sugata Manna, David Lindgren, Mattias Hölglund and Hakan Axelson

Hiroshi **Nakagawa** (Gastroenterology Division, University of Pennsylvania, USA) **12**

“Notch signaling regulates esophageal epithelial differentiation and tumor progression”

Authors: S. Ohashi, D. Stairs, K. Grugan, C. Michaylira, L. Kalabis, A. Capobianco, W. Pear, J. Katz, & H. Nakagawa

Ronan **O'Hagan** (AVEO Pharmaceuticals, Inc., USA) **13**

“Targeting the Tumor Maintenance Function of Notch for Cancer Therapy”

Authors: Heidi Okamura, Alisa Bell, Samantha Perino, Jeanine Lorusso, David Keane, Jenö Gyuris, Ronan O'Hagan

Clodia **Osipo** (Loyola University Medical Center, USA) **14**

“PEA3, an Ets Family Member, Regulates Notch-1 and Notch-4 Transcription in Breast Cancer”

Authors: Anthony G. Clementz, Antonio Pannuti, Lucio Miele, and Clodia Osipo

Rebecca **Rock** (University of Manchester, UK) **15**

“Notch signalling in DCIS and invasive breast cancer”

Authors: Rebecca Rock, Spyros Stylianou, Gillian Farnie, Robert B. Clarke, Nigel J. Bundred, and Keith Brennan

Aaron **Sato** (OncoMed Pharmaceuticals, USA) **16**

“A potent anti-Notch1 antibody blocks the ligand binding site and inhibits Notch dependent processes”

M. **Sonoshita** (Kyoto Univ. Grad. Sch. Med. (Pharmacol.), Japan) **17**

“Suppression of colon cancer metastasis by Aes through inhibition of Notch signaling”

Authors: M. Sonoshita, M.M. Taketo

Spyros **Stylianou** (Bank of Cyprus Oncology Centre, Cyprus) **18**

“Dominant negative Mastermind like for breast cancer treatment”

Authors: Spyros Stylianou, Christina Kousparou, Agamemnon Epenetos Spyros

Maria L. **Toribio** (Centro de Biología Molecular Severo Ochoa CSIC-UAM, Spain) **19**

“Notch signaling controls IL-7R expression and IL-7-dependent proliferation of T-ALL”

Authors: Sara Gonzalez-Garcia, Adolfo A. Ferrando, and Maria L. Toribio

Lizi **Wu** (University of Florida, U.S.A.) **20**

“ Identification of Notch pathway-specific target genes”

Authors: Jian-Liang Li, Shuibin Lin, Wenbin Liu, Lizi Wu

Koji **Yasutomo** (The University of Tokushima Graduate School of Medicine, Japan) **21**

“Dendritic cell-mediated NK cell activation is controlled by Jagged2-Notch interaction”

Authors: Mika Kijima, Yoichi Maekawa, Koji Yasutomo

LIST OF PARTICIPANTS

Iannis **AIFANTIS**, *Assistant Professor*

NYU- School of Medicine, Pathology

New York, , USA

T.: +1 212 22 635365

E- mail: iannis.aifantis@nyumc.org

Jon **ASTER**, *Associate professor*

Brigham & Women's Hospital, Pathology

75 Francis str, Boston, 02115, USA

T.: +1 617 525 7329, F.: +1 617 264 7369

E- mail: jaster@rics.bwh.harvard.edu

Irwin **BERNSTEIN**, *Member & Head*

Fred Hutchinson Cancer Research, Pediatric
Oncology Program

1100 Fairview Ave. N., Seattle, Washington,
98109, USA

T.: +1 206 667 1212, F.: +1 206 667 4086

E- mail: ibernste@fhcrc.org

Maurizio **BOCCHETTA**, *Assistant Professor*

Loyola University Medical Center, Oncology
Institute/ athology

2160 S. First Ave., Maywood, 60153, USA

T.: +1 708 327 3362, F.: +1 708 327 3238

E- mail: mbocche@lumc.edu

Sarah **BRAY**, *Professor*

University of Cambridge, Physiology &
Neuroscience

Downing Str, Cambridge, CB2 3DY, UK

T.: +44 1223 333792

E- mail: sjb32@cam.ac.uk

Robert **CALLAHAN**, *Principal Investigator*

National Cancer Institut, Mammary Biology &
Tumorigenesis Labora

Building 37/ Room 1118A, Bethesda, MD,
20892, USA

T.: +1 301 496 9871, F.: +1 301 402 0711

E- mail: rc54d@nih.gov

Andreas **ANDROUTSELLIS- THEOTOKIS**,
Contractor

NINDS, National Institut of health

35 Lincoln Drive, Bld. 35, Rm. 3A207,
Bethesda, Maryland, 20892, USA

T.: +1 301 4963412, F.: +1 301 4021340

E- mail: androuta@ninds.nih.gov

Hakan **AXELSON**, *Professor*

Lund University, Laboratory Medicine

U-MAS Entr 78, 2nd floor, Malmo, 20502,
SWEDEN

T.: +46 40 337621, F.: +46 4033 7063

E- mail: hakan.axelson@med.lu.se

Anna **BIGAS**, *Principal Investigator*

Fundacio IDIBELL, Molecular Oncology

Gran Via, s/n, km 2,7, Barcelona, 08907,
SPAIN

T.: +34 93 2607404

E- mail: abigas@idibell.org

Tilman **BORGGREFE**, *Group Leader*

Max- Planck Institute of Immunobiology,
Cellular & Molecular Immunobiology

Stuebeweg 51, Freiburg, 79108, GERMANY

T.: +49 761 5108 715, F.: +49 761 5108 799

E- mail: borggrefe@immunbio.mpg.de

Keith **BRENNAN**, *Senior Lecturer*

University of Manchester, Faculty of Life
Sciences

Michael Smith Building, Oxford rd.,
Manchester, M13 9Pt, UK

T.: +44 0 161 275 1517, F.: +44 0 161 275
1505

E- mail: keith.brennan@manchester.ac.uk

Anthony **CAPOBIANCO**,

Molecular and Cellular Oncogenesis Program

The Wistar Institute,
3601 Spruce Street, Philadelphia,
PA 19104, USA

T.: Tel: + 1 215 495-6816

E- mail: acapobianco@wistar.org

Spyros **ARTAVANIS-TSAKONAS**, *Professor*

Harvard Medical School,

Department of cell Biology

240 Longwood Ave, LHRRB-410A

Boston, MA 02115, USA

T.: + 1 617 4327048, F.: +1 617 432 7050

E- mail: artavanis@hms.harvard.edu

Diana **BELLAVIA**, *Research*

"Sapienza" University of Rome, exp. Medicine

V. le Regina Elena, 324, Rome, 00161, ITALY

T.: +39 6499 73026, F.: +39 644 64129

E- mail: diana.bellavia@unirome1.it

Stephen **BLACKLOW**, *Associate Professor*

Brigham & Women's Hospital, Pathology

77 Ave. Louis Pasteur, room 652E, Boston,
02115, USA

T.: +1 617 525 4415, F.: +1 617 525 4415

E- mail: sblacklow@rics.bwh.harvard.edu

Anna- Karin **BOSTROM**,

Lund University, CMP., Laboratory of Medicine

University Hospital MAS., Entr. 78, 2nd floor,
Malmo, 20502, SWEDEN

T.: +46 40 337903, F.: +46 40 337063

E- mail: anna-karin.bostrom@med.le.se

Meredith **CALDWELL**, *PhD Student*

Cancer research UK, Robinson Laboratory

Robinson Way, Cambridge, CB2 0RE, UK

T.: +49 01 223 404307

E- mail: meredith.caldwell@cancer.org.uk

David **CARBONE**, *Professor*

Vanderville Medical Center, Oncology

2220 Pierce Ave., PRB 777, Nashville, 37232,
USA

T.: +1 615 343 6404, F.: +1 615 936 3322

E- mail: david.p.carbone@vanderbilt.edu

Saula **CHECQUOLO**, *Post- Doctoral fellow*
"Sapienza" University of Rome, Exp. Medicine
V. le Regina Elena, 324, Rome, 00161, ITALY
T.: +39 649 973 311, F.: +39 644 64129
E- mail: saula.checquolo@uniroma1.it

Mark **CHIANG**, *Instructor*
University of Pennsylvania, Medicine
room 620, BRB 2/3, Philadelphia, 19104, USA
T.: +1 215 746 6578, F.: +1 215 573 6725
E- mail: chiangmarky@yahoo.com

Shigeru **CHIBA**, *Professor*
University of Tsukuba, Clinic Exp Hematol
Tennodai 1-1-1, Tsukuba, 305-8575, JAPAN
T.: +81 29 853 3103, F.: +81 29 853 3127
E- mail: schiba-tky@umin.net

Anthony **CLEMENTZ**, *PhD student*
Loyola University Medical Center, Molecular &
Cellular Biochemistry
2160 S. First Ave, Maywood, 60153, USA
T.: +1 708 327 3111, F.: +1 708 327 2245
E- mail: aclementz@lumc.edu,
PhysicChemist@aol.com

Natalie **COOK**, *Cilical Fellow*
Cancer research UK, Tuveson Laboratory
Robinson Way, Cambridge, CB2 0RE, UK
T.: +44 01 223 404307, F.: +44 01 223 404199
E- mail: natalie.cook@cancer.org.uk

Thao **DANG**, *Assistant Professor*
Vanderbilt Medical Center, Hematology/
Oncology
2220 Pierce Ave., PRB 777, , 37232, USA
T.: +1 415 936 1279, F.: +1 415 936 3322
E- mail: thao.p.dang@vanderbilt.edu

Giannino **DEL SAL**, *Professor*
University of Trieste, Moleculr Oncology
Padriciano 99, Trieste, 34012, ITALY
T.: +39 40 398979, F.: +39 40 398990
E- mail: raffaella.florit@incib.it

Christos **DELIDAKIS**, *Professor/ Collab.
Researcher*
FORTH, Institut Molec Biol & Biotechnol
Vassilika Vouton, Heraklion, 71110, GREECE
T.: +30 2810 391112, F.: +30 2810 391104
E- mail: delidaki@imbb.forth.gr

Maria **DOMINGUEZ- CASTELLANO**,
Professor
Instituto de Neurociencias, CSIC- UMH,
Neurobiology
Campus de San Juan, Apto.18, Alicante,
03550, SPAIN
T.: +34 965919390, F.: +34 965919561
E- mail: m.dominguez@umh.es

Gian- Paolo **DOTTO**, *Professor*
University of Lausanne, Biochemistry
Ch. Des Boveresses 155, Epalinges, 1066,
SWITZERLAND
T.: +41 21 692 5720, F.: +41 21 692 5705
E- mail: gian-paolo.dotto@unil.ch

Charles **EBERHART**, *Associate Professor*
Johns Hopkins University, Pathology
720 Rutland Ave- Ross Bldg 558, Baltimore,
21205, USA
T.: +1 410 502 5185, F.: +1 410 955 9777
E- mail: ceberha@jhmi.edu

Sean **EGAN**, *Senior Scientist*
The Hospital for Sick Children, Developmental
& Stem Cell Bio
101 College st., TMDT rm 14-309, Toronto,
M5G- 1L7, CANADA
T.: +1 416 813 5267, F.: +1 416 813 5252
E- mail: segan@sickkids.ca

Lluis **ESPINOSA**, *Principal Investigator*
Fundacio IDIBELL, Molecular Oncology
Gran Via, s/n, km 2,7, Barcelona, 08907,
SPAIN
T.: +34 93 2607404
E- mail: llespinosa@idibell.org

Xing **FAN**, *Assistant Professor*
University of Michigan, Neurosurgery
109 Zina Pitcher Place, Ann Arbor, 48109,
USA
T.: +1 734 615 7266, F.: +1 734 763 7322
E- mail: xingf@umich.edu

Adolfo **FERRANDO**, *Assistant Professor*
Columbia University, Institute for Cancer
Genetics
1130 St. Nicholas Ave., ICRC 505A, New York,
10032, USA
T.: +1 212 851 4611
E- mail: af2196@columbia.edu

Silvia **FRE**, *Post- Doc*
Institut Curie, Morphogenesis & Intracellular
Signalin
12 rue Lhomond, Paris, 75005, France
T.: +33 01 56 246362, F.: +33 01 56 246377
E- mail: silvia.fre@curie.fr

Christy **FRYER**, *Research Investigator*
Novartis Institutes for BioMedical Res.,
Developmental & Molecular Pathways
250 Massachusetts Ave. 5B- 263,
Cambridge, 02139, USA
T.: +1 617 871 4006, F.: +1 617 871 7262
E- mail: christy.fryer@novartis.com

Dmitry **GABRILOVICH**, *Professor*
H. Lee Moffitt Cancer Center, Immunology
MRC 2067, 12902 Magnolia Dr, Tampa,
33647, USA
E- mail: dmitry.gabrilovich@moffitt.org

Bastien **GERBY**
Commissariat à l'Energie Atomique
18 route du Panorama, Fontenay-aux-Roses,
92260, France
E- mail: bastien.gerby@cea.fr

Antonia **GOUNARI**, *Scientific Director*
Hellenistic Anticancer Institute, Research
Center
11 Valtetsiou str, Athens, 10680, GREECE
T.: +30 210 3643723, F.: +30 210 3643723
E- mail: antgouna@otenet.gr

Jeffrey **GREVE**, *Senior Director*
Exelixis,
210 East Grand Ave, San Francisco, 94083,
USA
T.: +1 650 837 8213
E- mail: jgreve@exelixis.com

Thomas **GRIDLEY**
Jackson Laboratory
600 Main str., Maine, 04609, USA
T.: +1 207 288 6237
E- mail: tom.gridley@jax.org

James **GRIFFIN**, *Chairman*
Dana Farber Cancer Institute, Medical
Oncology
44 Binney str., Boston, 02115, USA
T.: +1 617 632 3360, F.: +1 617 632 2260
E- mail: james_griffin@dfci.harvard.edu

Cynthia **GUIDOS**, *Senior Scientist*
The Hospital for Sick Children, Developmental
& Stem Cell Biology
TMDT Bldg., East Tower, 14th floor, Toronto,
M5G 1L7, CANADA
T.: +1 416 813 8810, F.: +1 416 813 8823
E- mail: cynthial.guidos@sickkids.ca

Neetu **GUPTA- ROSSI**, *Scientist*
Institut Pasteur, SMAC
25 rue du dr. Roux, Paris, 75015, France
T.: +33 1 40 61 3039, F.: +33 1 40 61 3040
E- mail: ngupta@pasteur.fr

Jeno **GYURIS**, *Senior Vice President*
AVEO Pharmaceuticals, Inc, Drug Discovery
75 Sydney Str, Cambridge, 01239, USA
T.: +1 617 299 5968, F.: +1 617 995 4995
E- mail: jgyuris@aveopharma.com

Meenard **HERLYN**, *Professor & Program
Leader*
The Wistar Institute,
3601 Spruce St., Philadelphia, PA 19104, USA
E- mail: mherlyn@wistar.org

Stefano **INDRACCOLO**, *Principal Investigator*
Istituto Oncologico Veneto
Via Gattamelata, 64, Padova, 35128, ITALY
T.: +39 0 498 215875, F.: +39 0 49 8072854
E- mail: stefano.indraccolo@unipd.it

S. Percy **IVY**, *Associate Chief, Senior
Investigator*
National Cancer Institut, Investigational Drug
Branch, CTEP, DCTD
EPN 7131, 6130 Executive Blvd, Rockville,
20852, USA
T.: +1 301 4961196, F.: +1 301 402 0428
E- mail: ivyp@ctep.nci.nih.gov

Paul **JOLICOEUR**, *Staff Scientist*
Institut of Montreal
110 west Pine Ave, Montreal, H2W 1R7,
CANADA
T.: +1 514 987 5569, F.: +1 514 987 5794
E- mail: jolicop@ircm.qc.ca

Hippokratis **KIARIS**, *Assistant Professor*
University of Athens, Medical School
Department of Biochemistry
Athens, Greece
T.: + 30 210 746695, F.: + 30-210-7462695
E- mail: hkiaris@med.uoa.gr

Jan **KITAJEWSKI**, *Associate Professor*
Columbia University, Pathology and Ob/ Gyn
1130 St. Nicholas Ave, New York, 10032, USA
T.: +1 212 851 4688
E- mail: jkk9@columbia.edu

Sudhir **KRISHNA**, *Professor*
National Centre for Biological Sciences,
Cellular Organization & Signalling
GKVK, Bellary Rd., Bangalore, 560065, INDIA
T.: +91 80 23666070, F.: +91 80 23636462
E- mail: skrishna@ncbs.res.in

Julian **LEWIS**, *Group Leader*
CRUK London Research Institute, Vertebrate
Development Institute
PO Box 123, 44 Lincoln's Inn Fields, London,
WC2A 3PX, UK
T.: +44 20 7269 3510, F.: +44 20 7269 3417
E- mail: julian.lewis@cancer.org.uk

Erick **LING**, *Graduate student*
Hospital for Sick Children, Development
Biology
101 College st., rm 13-308, Toronto, M5G 1L7,
CANADA
T.: +1 647 284 8127
E- mail: erick.ling@utoronto.ca

Shu- Hui **LIU**, *Senior Principal Scientist*
Riniat Laboratories, Pfizer Inc.
230 E Grand Ave, South San Fransisco,
94080, USA
T.: +1 650 615 7462, F.: +1 650 615 7350
E- mail: shu-hui.liu@pfizer.com

Raquel **MADEIRA GONCALVES**, *Post- Doc*
Institute of Biomedical Engineering,
Biomaterials Division
R. Campo Alegre, 823, Porto, 4150-180,
PORTUGAL
T.: +351 226074900, F.: +351 226094567
E- mail: raquelg@ined.up.pt

Marco **MAZZONE**, *Postdoctoral fellow*
Harvard Medical School, Cell Biology
240, Longwood Ave C1- 501, Boston, 02115,
USA
T.: +1 617 913 6422, F.: +1 617 432 3969
E- mail: marco_mazzone@hms.harvard.edu

Eleni **MELIOU**, *PhD candidate*
University of Athens, Dental School,
Endodontics
2 Thivon str., Athens, , GREECE
E- mail: emeliou@dent.uoa.gr

Sonia Anna **MINUZZO**, *Post Doc*
University of Padova, Oncology Surgical
Science
Via Gattamelata 64, Padova, 35128, ITALY
T.: +49 8215859, F.: +49 8072854
E- mail: soniaanna.minuzzo@unipd.it

Anders **MUTVEI**
Karolinska Institutet, CMB
Von Eulers vag 3, Stockholm, 17177,
SWEDEN
T.: +46 733 703647
E- mail: mutvei@gmail.com

Shinya **OHASHI**
University of Pennsylvania, Gastroenterology
Division
USA
E- mail: shinya@mail.med.upenn.edu

Sugata **MANNA**, *Post Doc. Fellow*
Lund University, CMP, Laboratory of Medicine
Univ. Hospital Mas., Entr- 78, 2nd floor,
Malmo, 20502, SWEDEN
T.: +46 40337903, F.: +46 40337063
E- mail: sugata-manna@med.le.se

John **McCAFFERTY**, *Director of Research*
Cambridge University, Biochemistry
80 Tennis Court Rd, Cambridge, CB2 1QW,
UK
T.: +44 1223 330747
E- mail: jm635@cam.ac.uk

Olivier **MEURETTE**, *Research Associate*
University of Manchester, Faculty of Life
Science
Michael Smith Building, Oxford Rd.,
Manchester, M13 9PT, UK
T.: +44 0 161 2751524
E- mail: olivier.meurette@manchester.ac.uk

Thimios **MITSIADIS**, *Professor*
University of Zurich, Institute Oral Biology
Plattenstrasse 11, Zurich, 8046,
SWITZERLAND
T.: +41 44 634 33 90
E- mail: thimios.mitsiadis@zzmk.uzh.ch

Hiroshi **NAKAGAWA**, *Professor of Medicine*
University of Pennsylvania, Gastroenterology
Division
USA
T. : + 215 573 1867, F. : + 215 573 2024
E- mail: nakagawah@mail.med.upenn.edu

Barbara **OSBORNE**, *Professor*
University of Massachusetts, Vat & Animal
Sciences
311 Paige Lab, Amherst, MA, 01003, USA
T.: +1 413 545 4882, F.: +1 413 545 1446
E- mail: osborne@vasci.umass.edu

Marc **MANSOUR**, *Clinical Research Training
Fellow*
University College Hospital, Haematology
Cancer Institute, London, WC1E 6BT, UK
T.: +44 777 589 6426
E- mail: marcmasour@yahoo.com

Ronald **McKAY**,
NINDS, National Institut of health
35 Lincoln Drive, Bld. 35, Rm. 3A207,
Bethesda, Maryland, 20892, USA
E- mail: mckay@codon.nih.gov

Lucio **MIELE**, *Professor*
Loyola University, Cancer Center
2160 S. 1st Ave., Maywood, 60153, USA
T.: 7083273298, F.: 7083272245
E- mail: lmiele@lumc.edu

Julien **MORETTI**, *PhD student*
Institut Pasteur, SMAC
25 rue du Dr. Roux, Paris, 75015, France
T.: +33 1 40 61 3041, F.: +33 1 40 61 3040
E- mail: jmoretti@pasteur.fr

Ronan **O' HAGAN**, *Principal Scientist*
AVEO Pharmaceuticals, Inc, Target biology
75 Sidney st., 4th floor, Cambridge, 02139,
USA
T.: +1 617 299 5960, F.: +1 617 995 4995
E- mail: rohagan@aveopharma.com

Clodia **OSIPO**, *Assistant Professor*
Loyola University Medical Center, Pathology
2160 S. First Ave, Maywood, 60153, USA
T.: +1 708 327 2372, F.: +1 708 327 2245
E- mail: cosipo@lumc.edu

Konstantinos **PAPAZIS**, *Lab Head, Medical Oncologist*

Theagenion Cancer Hospital, Applied molecular cancer hospital

Al. Simeonidi str., Thessaloniki, 54007, GREECE

T.: +30 2310 898704, F.: +30 2310 898753 E-mail: kpapazisis@the.forthnet.gr

Freddy **RADTKE**, *Group Leader*

EPFL SV ISREC

Chemin des Boveresses 155, Epalinges, 1066, SWITZERLAND

T.: +41 21 692 5964, F.: +41 21 652 6933

E-mail: freddy.radtke@epfl.ch

Rossella **ROTA**, *Senior Scientist, Ph.D.*

Endothelial Cells Lab., Ospedale Pediatrico Bambino Gesù

Piazza S. Onofrio 4, Rome, 00165, ITALY

T.: +39 0 668592648, F.: +39 0 668592904

E-mail: rota@opbg.net

Isabella **SCREPANTI**, *Professor*

Sapienza university of Rome, Experimental Medicine

Viale Regina Elena 324, Roma, 00161, ITALY

T.: +39 644 700816, F.: +39 644 64129

E-mail: isabella.screpanti@uniroma1.it

Stefano **STIFANI**, *Professor*

McGill University, Montreal Neurological Institut

3801 rue University, Montreal, H3A 2B4, CANADA

T.: +1 514 398 3946, F.: +1 514 398 1319

E-mail: stefano.stifani@mcgill.ca

Makoto Mark **TAKETO**, *Professor*

Pharmacology

Yoshiba- Konoe- cho, Sakyo, Kyoto, 606-8501, JAPAN

T.: +81 75 753 4391, F.: +81 75 753 4402

E-mail: taketo@mfour.med.kyoto-u.ac.jp

Warren S. **PEAR**, *Associate Professor*

University of Pennsylvania, Pathology

611 Brb 2/3; 421 Curie lvd, Philadelphia, 19104- 6160, USA

T.: +1 215 573 7764, F.: +1 215 573 6725

E-mail: wpear@mail.med.upenn.edu

Sylvie **ROBINE**, *Senior Scientist*

Institut Curie, UMR 144

26 rue d' ULM, Paris, 75248, France

T.: +33 1 56 246361, F.: +33 1 56 246377

E-mail: sylvie.robine@curie.fr

Alessandra **RUSTIGHI**, *Post- Doc*

National Laboratory CIB, Molecular Oncology

Padriciano 99, Trieste, 34012, ITALY

T.: +39 040 3756800, F.: +39 040 398990

E-mail: alessandra.rustighi@incib.it

Chris **SIEBEL**, *Senior Scientist*

Genentech, Molecular Biology

1 DNA Way, MS #37, South San Fransisco, 94080, USA

T.: +1 650 225 2751, F.: +1 650 225 6412

E-mail: csiebel@gene.com

Spyros **STYLIANOU**, *Principal Investigator*

Bank of Cyprus Oncology Centre

CYPRUS

T.: +357 22841393, F.: +357 22516425

E-mail: spyros.stylianou@cytanet.com.cy

Gavin **THURSTON**, *Sr. Director*

Regeneron Pharmaceuticals, Oncology & Angiogenesis

777 Old Saw Mill River Rd, Tarrytown, NY, 10591, USA

T.: +1 914 345 7575, F.: +1 914 347 5045

E-mail: gavin.thurston@regeneron.com

Francoise **PFLUMIO**, *Phd, Team Leader*

Commissariat à l'Energie Atomique

18 route du panorama, Fontenay-aux-Roses, 92260, France

T.: +33-1-46-54-86-17, F.: +33--1-46-54-91-38

E-mail: francoise.pflumio@cea.fr

Rebecca **ROCK**, *Research Associate*

University of Manchester, Faculty of Life Science

Michael Smith Building, Oxford Rd., Manchester, M13 9PT, UK

T.: +44 0 161 2755576

E-mail: rebecca.e.rock@manchester.ac.uk

Aaron **SATO**, *Sr. Director*

Antibody Engineering,

800 Chesapeake Dr., Redwood, 94063, USA

T.: +1 650 995 8221, F.: +1 650 298 8600

E-mail: aaron.sato@oncomed.com

Masahiro **SONOSHITA**, *Assistant Professor*

Kyoto University, Pharmacology

Yoshida- Konoe- Cho, Sakyo- ku, Kyoto, 606-8501, JAPAN

T.: +81 75 753 4401, F.: +81 75 753 4402

E-mail: m-sonoshita@mfour.med.kyoto-u.ac.jp

Youping **SUN**, *Research Fellow*

Harvard Medical School, Cell Biology

LHRRB 418/240 Longwood Ave, Boston, 02115, USA

T.: +1 617 432 7055, F.: +1 617 432 7050

E-mail: youping_sun@hms.harvard.edu

Maria L. **TORIBIO**, *Head of group*

Centro Biología Molecular Severo Ochoa, Immunology and Cell Biology

Univ. Autónoma MadridC/ Nicolas Cabrera1, Cantoblanco, Madrid, 28049, SPAIN

T.: +34 9199 64 556, F.: +34 911 964420

E-mail: mtoribio@cbm.uam.es

Panagiota **TOUPLIKIOTI**, *Lab. Manager, Biologist*

Theagenion Cancer Hospital, Applied
Molecular Oncology Lab

Al. Simeonidi str., Thessaloniki, 547007,
GREECE

T.: +30 2310 898278

E- mail: gtouplik@yahoo.gr

Koji **YASUTOMO**, *Professor*

The University of Tokushima, Immunology

Japan

E- mail: yasutomo@basic.med.tokushima-
u.ac.jp

Marc **VOOIJIS**, *Group Leader*

University Utrecht Medical Center, Pathology

Heidelberglaan 100, Utrecht, 3584 CX,
NETHERLANDS

T.: +31 88 7558316, F.: +31 30 2544990

E- mail: m.vooijs@umcutrecht.nl

Lizi **WU**, *Assistant Professor*

University of Florida, Molecular Genetics &
Microbiology

1376 Mowry Rd., Gainesville, 32610, USA

T.: +1 352 273 8205, F.: +1 352 273 8299

E- mail: lzwu@ufl.edu

Bin- Bing **ZHOU**, *Senior Director*

Wyeth Pharmaceuticals, Oncology

401 N. Middletown rd., Pearl river, NY, 10965,
USA

T.: +1 845 602 1924, F.: +1 845 602 5557

E- mail: zhoub@wyeth.com



Fondation Santé was established in 2000 as a private foundation operating exclusively for charitable, scientific and educational purposes. The foundation aims to assist in advancing the health and education of those in need, whether individuals, regions or countries.